Spyre Therapeutics, Inc. (SYRE) Price Target Analysis
Updated Jun 26, 2026
Analyst Rating: Buy
Based on 11 analysts8.5% Below Target
SYRE trades 8.5% below Wall Street's consensus target of $95.40.
Current Price$87.89
Average Target$95.40
Target
Current
Low$49.00
Median$95.00
High$135.00
Analyst Target Range
Forward P/E—
PEG Ratio—
Implied Growth-480.8%
(Declining)
Analyst Spread90.1%
(Wide Disagreement)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes SYRE achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 11 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
SYRE Price Target Analysis
Updated June 28, 2026As of June 28, 2026, Spyre Therapeutics, Inc. (SYRE) has a Wall Street consensus price target of $95.40, based on estimates from 11 covering analysts. With the stock currently trading at $87.89, this represents a potential upside of +8.5%. The company has a market capitalization of $30.41B.
Analyst price targets range from a low of $49.00 to a high of $135.00, representing a 90% spread in expectations. The median target of $95.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 11 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, SYRE trades at a trailing P/E of -44.4x. Analysts expect EPS to grow -480.8% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+30.6%
Industry Consensus
Avg Forward P/E
44.7x
(Growth Premium)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ARRYArray Technologies, Inc. | $1.1B | $7.12 | $9.80 | +37.6% | Buy | 9.8x | 28 |
 PRTAProthena Corporation plc | $525M | $10.02 | $19.00 | +89.6% | Buy | 214.6x | 28 |
 TRMBTrimble Inc. | $12.0B | $50.70 | $90.50 | +78.5% | Buy | 16.4x | 28 |
 PTGXProtagonist Therapeutics, Inc. | $7.8B | $121.88 | $117.25 | -3.8% | Buy | 30.2x | 26 |
 TERNTerns Pharmaceuticals, Inc. | $4.8B | $52.95 | $55.50 | +4.8% | Buy | — | 16 |
 JANXJanux Therapeutics, Inc. | $911M | $14.94 | $23.83 | +59.5% | Buy | — | 15 |
 ABBVAbbVie Inc. | $444.4B | $251.52 | $258.00 | +2.6% | Buy | 17.7x | 41 |
 JNJJohnson & Johnson | $613.0B | $254.66 | $253.42 | -0.5% | Buy | 22.0x | 40 |
 LLYEli Lilly and Company | $1.1T | $1206.51 | $1269.94 | +5.3% | Buy | 33.0x | 45 |
 REGNRegeneron Pharmaceuticals, Inc. | $65.8B | $632.90 | $836.00 | +32.1% | Buy | 13.6x | 48 |
SYRE — Frequently Asked Questions
Quick answers to the most common questions about buying SYRE stock.
What is the SYRE stock price target for 2026?
The consensus price target for SYRE is $95.4, close to the current price of $87.89 (8.5% implied move). Based on 11 analyst estimates, the stock appears fairly valued near current levels.
Is SYRE a buy, sell, or hold?
SYRE has a consensus rating of "Buy" based on 11 Wall Street analysts. The rating breakdown is predominantly bullish, with 11 Buy/Strong Buy ratings. The consensus 12-month price target of $95.4 implies 8.5% upside from current levels.
Is SYRE stock overvalued or undervalued?
SYRE's current price is $87.89 with a consensus target of $95.4 (8.5% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
How high can SYRE stock go?
The most bullish Wall Street analyst has a price target of $135 for SYRE, while the most conservative target is $49. The consensus of $95.4 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover SYRE stock?
SYRE is moderately covered, with 11 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 11 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the SYRE stock forecast?
The 12-month SYRE stock forecast based on 11 Wall Street analysts shows a consensus price target of $95.4, with estimates ranging from $49 (bear case) to $135 (bull case). The median consensus rating is "Buy".
Should I buy SYRE stock?
SYRE appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $95.4 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do SYRE price targets vary so much?
SYRE analyst price targets range from $49 to $135, a 90% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $95.4 consensus represents the middle ground.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare